Perioperative Treatment in EGFR‐Mutant Early‐Stage Non‐Small Cell Lung Cancer: Current Evidence and Future Perspectives

Perioperative Treatment in EGFR‐Mutant Early‐Stage Non‐Small Cell Lung Cancer: Current Evidence and Future Perspectives

ABSTRACT Adjuvant osimertinib administered over a 3‐year period in patients diagnosed with stage IB–IIIA non‐small cell lung cancer (NSCLC) and epidermal growth factor receptor (EGFR) mutations has not only shown improvement in event‐free survival but also demonstrated a prolonged overall survival (...

Full description

Saved in:
Bibliographic Details
Main Authors: Xiaobei Guo, Xiaoyan Liu, Chao Guo, Qian Miao, Xinghua Cheng, Xuan Hong, Hongru Li, Xiaoming Qiu, Yi Xiang, Di Zheng, Jian Zhou, Liyan Jiang, Yan Xu, Mengzhao Wang
Format: Article
Language:English
Published: Wiley 2025-02-01
Series:Thoracic Cancer
Subjects:
adjuvant targeted therapy
ctDNA
early‐stage NSCLC
EGFR‐mutant
neoadjuvant immunotherapy
neoadjuvant targeted therapy
Online Access:https://doi.org/10.1111/1759-7714.70018
Tags: Add Tag
No Tags, Be the first to tag this record!

Internet

https://doi.org/10.1111/1759-7714.70018

Similar Items